Company Profile - 关于我们

Global

Company Profile

Lepu Biopharma Co., Ltd. is an innovation-driven biopharmaceutical company focusing on oncology therapeutics, in particular, targeted therapy and oncology immunotherapy, with a strong China foundation and global vision. We are dedicated to developing innovative ADCs through an advanced ADC technology development platform. We aim to develop more optimal and innovative drugs to better serve the unmet medical needs of cancer patients. We endeavor to continuously develop a market-differentiating pipeline by combining in-house research and development as well as strategic collaborations, strengthen our in-house manufacturing capabilities and commercialize our pipeline products in China through dedicated sales and marketing forces, and internationally via partnerships. We have an integrated end-to-end capability across drug discovery, clinical development, CMC and GMP-compliant manufacturing, encompassing critical functions of the biopharmaceutical value chain, and are building dedicated sales and marketing forces.

Innovative drug screening and optimization
Clinical research and development
Product manufacturing and commercialization

Milestones

Scroll down to see more

Drag the mouse to the left to see more

Core Team

Pu Zhongjie

Executive Director and Chairman

Dr. Pu Zhongjie is the founder and Controlling Shareholder of the Group, serving as our executive Director and the chairman of our Board, director and the chairman of the board of Taizhou Aoke, director of Miracogen Shanghai and executive director of Lepu Beijing.

In addition to his position at Lepu Biopharma, Dr. Pu has consecutively held positions with Lepu Medicalas its director, chief technology officer, general manager, vice chairman of the board and chairman of the board and is currently the chief technology officer and chairman of the board of Lepu Medical. Dr. Pu also serves as an executive director of Beijing Tiandi Harmony Technology Co., Ltd. (北京天地和協科技有限公司), a wholly owned subsidiary of Lepu Medical engaging in the medical device business. Further, Dr. Pu has been serving as an executive director and the general manager of Beijing Puping Tiancheng Investment Management Consulting Co., Ltd. (北京普平天成投資管理顧問有限公司), a company ultimately owned by Dr. Pu as to 100% and licensed to conduct investment consulting business, In addition, Dr. Pu has also been serving as an executive director and the general manager of Huarui Zongheng, an executive director and the general manager of Beijing Houde Yimin, an executive director and the general manager of Ningbo Houde Yimin, an executive director and the general manager of Ningbo Houde Yimin Investment Management Co., Ltd. (寧波厚德義民投資管理有限公司), a company wholly owned by Beijing Houde Yimin, and served as an independent director of Beijing Jinyi Culture Development Joint Stock Company (北京金一文化發展股份有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 002721). Prior to establishing Lepu Biopharma, Dr. Pu served as deputy general manager of technology department of U.S. WP Medical Technologies, Inc.

Dr. Pu obtained a bachelor’s degree in mechanical engineering in metal materials from Xi’an Jiaotong University (西安交通大學) in the PRC in 1983, a master’s degree in metal materials from Xi’an Jiaotong University (西安交通大學) in the PRC in 1985, and a doctoral degree in metal materials from Central Iron & Steel Research Institute (鋼鐵研究總院) in the PRC in July 1990.
Sui Ziye

Executive Director and Chief Executive Officer

Dr. Sui Ziye is our executive Director and the chief executive officer of our Company, a director of Miracogen Shanghai, a director of Taizhou Aoke, an executive director of CtM Bio, and the general manager of Lepu Beijing. In addition, Dr. Sui also serves as a director of Hangzhou HealSun, a company owned by us as to 23.2% . Dr. Sui has nearly ten years of managerial experience in the pharmaceutical sector.

Prior to joining our Group, Dr. Sui held several positions at Lepu Medical and its subsidiaries, including an international sales & marketing manager and a vice president of Lepu Medical, a CEO of Comed BV, a CEO of Beijing Lepu Hushengtang Technology Co., Ltd. (北京樂普護生堂網絡科技有限公司), an executive director of Beijing Star GK Medical Device Co., Ltd. (北京思達醫用裝置有限公司), the chairman of the board of Zhongcheng Healthcare Industrial (Hainan) Co., Ltd. (中鋮健康產業(海南)股份有限公司), previously known as Hainan Mingshengda Pharmaceutical Co., Ltd. (海南明盛達藥業有限公司), and a director of Beijing Quinovare Medical Technology Co., Ltd. (北京快舒爾醫療技術有限公司).

Dr. Sui obtained a bachelor’s degree in medical science from Peking University (北京大學) in the PRC in 2001 and a doctoral degree from University of Rochester in the U.S. in 2007.
Qin Minmin

Chief Technology Officer

Prior to joining the Group, Dr. Qin served as (a) a senior vice president and head of CMC department of HBM Holdings Limited (和鉑醫藥控股有限公司), a company listed on the Stock Exchange (stock code: 02142), from March 2018 to April 2019, (b) a vice president of Wuxi Biologics (Cayman) Inc. (藥明生物技術有限公司), a company listed on the Stock Exchange (stock code: 02269), from August 2017 to March 2018, (c) a chief science officer of Jiangsu Pacific Meinuoke Pharmaceutical Co., Ltd. (江蘇太平洋美諾克生物藥業有限公司) from October 2016 to July 2017, (d) a chief technology officer as well as a senior vice president of Zhejiang Teruisi Pharmaceutical Co., Ltd. (浙江特瑞思藥業股份有限公司) from September 2015 to October 2016, (e) a chief technology officer of Shanghai JMT – Bio, Inc. from September 2012 to September 2015, (f) a senior director of Five Prime Therapeutics, a company listed on the Nasdaq Stock Exchange (stock code: FPRX), from January 2005 to August 2012, and (g) various positions, including senior director of process development, in BioMarin Pharmaceutical Inc., a company listed on the Nasdaq Stock Exchange (stock code: BMRN), from May 1997 to October 2004.

Dr. Qin obtained a bachelor’s degree in agriculture from Northwest Agriculture and Forest University (西北農林科技大學), previously known as Northwest Agriculture College (西北農學院), in the PRC in December 1981, a doctoral degree from University of Wisconsin Madison in the U.S. in May 1991, and a completed a post-doctoral research from the University of California Berkeley in the U.S. in April 1997.

Dr. Qin is an adjunct professor of Xi’an Jiaotong University (西安交通大學) from June 1, 2016 to June 1, 2021. Dr. Qin was awarded Rusty Award from Five Prime Therapeutics in both 2010 and 2011.
Fang Lei

Vice President

Dr. Fang is the vice president of the Company and the general manager of CtM Bio. Dr. Fang has more than ten years of experience in oncology clinical drug development and is an expert in immunology, development strategy and early-stage clinical trials for innovative drugs and translational medical science.

Prior to joining the Group, Dr. Fang served as a director and then executive director of research and development department of I-Mab Shanghai, a subsidiary ultimately and wholly owned by I-Mab, a company listed on the New York Stock Exchange (stock code: IMAB), from September 2016 to April 2020, a director of Third Venture Biopharma (Nanjing) Co., Ltd. (南京三境生物科技有限公司), the predecessor of I-Mab, from March 2015 to August 2016, and consecutively as a research fellow and scientist of GSK (Shanghai) Drug Development Co., Ltd. (葛蘭素史克(上海)醫藥研發有限公司) from June 2010 to February 2015.

Dr. Fang obtained a bachelor’s degree in biotechnology from Hebei University (河北大學) in the PRC in June 2004 and a doctoral degree in cell biology from Chinese Academy of Sciences (中國科學院). Dr. Fang received an R&D’s Exceptional Science Award (卓越科學成就獎) from GSK (Shanghai) Drug Development Co., Ltd. in 2013.